precision oncology
Yemaachi News
February 14, 2023
As one of Ghana's only labs equipped for molecular analysis, Bediako's team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
November 29, 2022
As one of Ghana's only labs equipped for molecular analysis, Bediako's team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
May 25, 2022
As one of Ghana's only labs equipped for molecular analysis, Bediako's team have tasked themselves with collecting data they believe will advance the development of medicine for cancer patients throughout the continent and diaspora
March 21, 2022
Yemaachi Biotech announced today the close of a $3 million seed round to advance its mission of diversifying precision oncology globally. V8 Capital led the round, with LifeLine Family Heritage Fund, Y Combinator, Tencent, LoftyInc Capital, VestedWorld, V Square Capital and Ethan Perlstein also participating.
November 3, 2021
GenomeWeb covers Yemaachi's collaboration with cancer liquid biopsy firm Lucence to document and characterize the genomics of breast cancer in women of African descent.
October 26, 2021
PALO ALTO, Calif. & ACCRA, Ghana--(BUSINESS WIRE)--Lucence, a precision oncology company using liquid biopsy to bring clarity to cancer care, and Yemaachi Biotech, a cancer research company based in Accra, Ghana, announced today that they are collaborating on a study to better characterize and understand the genomics of breast cancer in women of African descent.